Atypical Antipsychotics Induced Metabolic Syndrome
The use of atypical antipsychotics in patients with schizophrenia is tightly related to the metabolic abnormalities like weight gain, diabetes, dyslipidemia and/or hypertension. Beside of having unique receptor binding features, their heterogeneous receptor binding properties ara also involved in th...
Main Authors: | Aysegul Demirel, Omer Faruk Demirel, Mufit Ugur |
---|---|
Format: | Article |
Language: | English |
Published: |
Psikiyatride Güncel Yaklaşımlar
2015-03-01
|
Series: | Psikiyatride Güncel Yaklaşımlar |
Subjects: | |
Online Access: | http://www.cappsy.org/archives/vol7/no1/cap_07_01_07.pdf |
Similar Items
-
Hyperhomocysteinemia in Treatment with Atypical Antipsychotics is Independent of Metabolic Syndrome
by: Emre Sarandöl, et al.
Published: (2023-12-01) -
Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics
by: Anastasiia S. Boiko, et al.
Published: (2021-05-01) -
Clozapine: A special case of an atypical antipsychotic
by: Elina Marinho
Published: (2024-04-01) -
Atypical antipsychotics in the treatment of schizophrenia
by: Swiss Medical Weekly
Published: (2003-02-01) -
Metabolic and Endocrine Side Effects of Atypical Antipsychotic Drugs in Children and Adolescents
by: Aysegul Tahiroglu, et al.
Published: (2011-03-01)